Monday, November 15, 2021

Mingsight Gets $20M

San Diego-based MingSight Pharmaceuticals, a company that is developing treatments for chronic lymphocytic leukemia and diabetic macular edema, says it has raised $20M in a pre-Series B funding round. The funding was led by Kaitai Capital. According to the company, the proceeds of the funding will go towards clinical development of its product. Kai Zhang is CEO and co-founder of MingSight. The company says it is developing treatments for B-cell malignancies, diabetic macular edema, and autoimmune diseases. More information »